Project description:Obacunone treatment slightly changes gene expression of cholesterol metabolism-associated genes in HepG2 cells Total RNA obtained from HepG2 cells treated with 100 uM obacunone for 0.5, 1, 3, 6, or 12 h was compared to that of vehicle control cells.
Project description:This experiment series addresses the role of coactivator SRC-1/NcoA-1 for the induction of interleukin-6 (IL-6) target genes in HepG2 cells. For that purpose, HepG2 human hepatocellular carcinoma cells were manipulated to stably express an shRNA that knocks down SRC-1 expression yielding the HepG2-âSrc1 cells. Either unmanipulated HepG2 or HepG2-âSrc1 cells were then treated for various periods with IL-6. Experiment Overall Design: HepG2 or HepG2-âSrc1 (with silenced SRC-1/NcoA-1 expression) cells were either left untreated or treated with 10 ng/ml IL-6 for 1 or 4 hours. Every experiment was carried out in replicate.
Project description:APRIL (TNFSF13) is a ligand of the TNF superfamily which binds to two receptors, BCMA and TACI. We have found that APRIL and its receptor BCMA are specifically enhanced in hepatocellular carcinoma, as compared to non-cancerous liver tissue. We further identified that HepG2 cells present the same ligand/receptor pattern as human hepatocellular carcinomas. We investigated the role of APRIL in HepG2 gene expression in a time course study. 24 hour serum starved HepG2 cells were treated with 200ng/ml of APRIL and RNA was collected at 0, 2, 6, and 12h. The collected RNA was used for hybridization on commercially available Affymetrix Human Genome U133 Plus 2.0 Arrays
Project description:This experiment series addresses the role of coactivator SRC-1/NcoA-1 for the induction of interleukin-6 (IL-6) target genes in HepG2 cells. For that purpose, HepG2 human hepatocellular carcinoma cells were manipulated to stably express an shRNA that knocks down SRC-1 expression yielding the HepG2-∆Src1 cells. Either unmanipulated HepG2 or HepG2-∆Src1 cells were then treated for various periods with IL-6. Keywords: time course, genetic modification
Project description:To identify p53-regulated lncRNAs responsive to DNA damage in human hepatocellular carcinoma (HCC) cells, we conducted paired-end and strand-specific RNA-seq using HepG2 wild-type and p53-knockout (HepG2-KO-p53) cells, which were devoid of p53 protein, using the CRISPR-Cas9 system treated with or without the DNA-damaging agent adriamycin (ADR)
Project description:Investigation of whole genome gene expression level changes in hepatocellular carcinoma cell line hepG2 in regular culture, hepG2-slug in regular culture and hepG2-slug on Matrigel. Whole genome gene expression level changes have been compared in hepatocellular carcinoma cell line hepG2 in regular culture, hepG2-slug in regular culture and hepG2-slug on Matrigel. Roche NimbleGen micro-array analysis was employed to assess global genome expression in HepG2 in regular culture, HepG2-slug in regular culture and HepG2-slug on Matrigel. The results demonstrated that the up-regulated genes and the down-regulated genes increased significantly when HepG2-slug cells with VM forming ablity were cultured on Matrigel and formed VM.
